{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-22-000041","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.276594+00:00","generated_at":"2026-06-24T01:49:56.052862+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ClearPoint Neuro Q2 revenue record $5.2M (+52% YoY); reaffirms 2022 guidance","bullets":["Quarterly revenue $5.2M (record), up 52% YoY; biologics/drug delivery revenue $2.4M +73%.","Partner PTC Therapeutics received EU marketing authorization for Upstaza; uses ClearPoint SmartFlow Neuro Cannula.","Reaffirmed FY2022 revenue guidance of $21-22M.","Cash and short-term investments $45.1M at June 30, 2022.","Added >45 partners; installed 8 systems YTD (4 in Q2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-22-000041","json":"https://secwatch.observer/filing/0001285550-22-000041.json","markdown":"https://secwatch.observer/filing/0001285550-22-000041.md","text":"https://secwatch.observer/filing/0001285550-22-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555022000041/0001285550-22-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555022000041/clpt-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:49:56.052862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}